08th week of 2016 patent applcation highlights part 21 |
Patent application number | Title | Published |
20160052847 | PRODUCTION OF PARTIALLY REFINED WASTE GLYCEROL - The disclosure relates to a novel glycerol purification process that produces partially refined waste glycerol for a variety of industrial applications. The disclosure encompasses a salt-containing partially refined glycerol composition that is suitable as a fermentation grade glycerol. | 2016-02-25 |
20160052848 | METHOD FOR PRODUCING CYCLOALKYL ALKYL ETHER COMPOUND - The present invention is a method for producing a cycloalkyl alkyl ether compound comprising reacting substituted or unsubstituted cyclopentene or substituted or unsubstituted cyclohexene with an alcohol compound represented by a formula (2): R | 2016-02-25 |
20160052849 | High-Purity Monoalkenyl-Containing Glycerin Derivative, And Method For Producing Same - The present invention relates to a monoalkenyl-containing glycerin derivative with purity of not less than 92% and electrical conductivity of not greater than 50 μS/cm. The monoalkenyl-containing glycerin derivative can be manufactured by a manufacturing method comprising a step (A): a step of reacting a ketalized glycerin derivative and a monoalkenyl glycidyl ether in the presence of an inorganic base to obtain a ketal of monoalkenyl-containing glycerin derivative; a step (B): a step of purifying the ketal of monoalkenyl-containing glycerin derivative obtained in the step (A) by distillation; and a step (C): a step of hydrolyzing the ketal of monoalkenyl-containing glycerin derivative obtained in the step (B). The present invention is able to provide a high-purity monoalkenyl-containing glycerin derivative that was difficult in the past. It is further able to provide a glycerin derivative-modified silicone, and applications therefor, that is chemically stable, and further has excellent utility for its emulsifiability, and the like, and excellent formulation stability. | 2016-02-25 |
20160052850 | Solubilization of Pterostilbene and Resveratrol in Aqueous Beverages - In one embodiment, the present application discloses compositions and methods of solubilizing pterostilbene or resveratrol, or mixture thereof in aqueous media. | 2016-02-25 |
20160052851 | A METAL-DOPED HYDROXYAPATITE CATALYST - The present invention provides the use of a metal-doped hydroxyapatite catalyst for highly selective conversion of an alcohol to an aldehyde at low temperatures. More specifically, the invention provides the use of a silver-doped hydroxyapatite catalyst for the highly selective oxidative dehydrogenation of ethanol to acetaldehyde. The present invention also provides the method for converting ethanol to acetaldehyde using a silver-doped hydroxyapatite catalyst. | 2016-02-25 |
20160052852 | METHOD FOR PRODUCING DIALDEHYDE - Provided is an industrially advantageous method for producing a dialdehyde having a production ratio of linear dialdehydes to branched dialdehydes of 80/20 to 90/10, with an amount of rhodium to be used that is lower than that in the related art. Specifically, provided is a method for producing a dialdehyde, including reacting a linear olefinic compound having each of an ethylenic double bond and an aldehyde group on each end of the molecule with carbon monoxide and hydrogen, in the presence of a rhodium catalyst comprised of a bisphosphite represented by General Formula (I) and a rhodium compound, in which the reaction pressure of a mixed gas formed of carbon monoxide and hydrogen is decreased as the reaction proceeds, wherein R represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms, and W represents an alkylene group having 1 to 20 carbon atoms, a cycloalkylene group having 5 to 18 carbon atoms, or an alkylene-arylene group having 7 to 11 carbon atoms, and a rhodium compound. | 2016-02-25 |
20160052853 | PLATE-TYPE REACTOR WITH IN-SITU INJECTION - A chemical reactor including: a plurality of heat exchange plates which between them define reaction compartments, in which reactor each heat exchange plate includes two walls between them defining at least one heat exchange space, the respective walls being fixed together by joining regions, and the reactor also comprises at least one injection device for injecting substance into the reaction compartments, said substance-injection device passing through the heat-exchange plates in respective joining regions thereof. Also, a chemical reaction process that can be carried out in this reactor. | 2016-02-25 |
20160052854 | METAL-CATALYZED COUPLING OF ARYL AND VINYL HALIDES WITH ALPHA, ALPHA-DIFLUOROCARBONYL COMPOUNDS - The coupling of aryl, heteroaryl, and vinyl halides with α,α-difluoroketones or silyl ethers or siylenol ethers of α,α-difluoroketones and α,α-difluoroamides and esters are described. Further derivatization of the coupling products (such as ketone cleavage and Baeyer-Villiger oxidation) is also described. | 2016-02-25 |
20160052855 | PERFUME COMPOSITIONS CONTAINING ISOMERIC ALKADIENALS - A perfume composition comprising an effective amount of at least one alkadienal selected from 4,8-undecadienal and isomers thereof, 4,9-dodecadienal and isomers thereof, and 4,10-tridecadienal and isomers thereof. The isomers of 4,8-undecadienal comprise Z,Z-4,8-undecadienal, E,E-4,8-undecadienal, and mixed Z/E isomers of 4,8-undecadienal; the isomers of 4,9-dodecadienal comprise Z,Z-4,9-dodecadienal, E,E-4,9-dodecadienal, and mixed Z/E isomers of 4,9-dodecadienal; and the isomers of 4,10-tridecadienal comprise Z,Z-4,10-tridecadienal, E,E-4,10-tridecadienal, and mixed Z/E isomers of 4,10-tridecadienal. A composition comprising an effective amount of at least one alkadienal selected from 4,8-undecadienal and isomers thereof, 4,9-dodecadienal and isomers thereof, and 4,10-tridecadienal and isomers thereof. Processes for the preparation of the isomer mixtures of alkadienals are provided. The isomeric alkadienals have a range of fresh, watery, ozone, grapefruit, tangerine, orange peel, aldehydic notes of exceptional strength. | 2016-02-25 |
20160052856 | Beta-HYDROXY-Beta-METHYLBUTYRIC ACID PURIFICATION METHOD - The present invention relates to a method for purifying β-hydroxyl-β-methyl butyrate, comprising neutralizing a crude β-hydroxyl-β-methyl butyrate with a base to produce a salt of β-hydroxyl-β-methyl butyrate, cooling and crystallizing, dissolving and acidifying, and extracting to obtain β-hydroxyl-β-methyl butyrate of high purity. No strict conditions, such as high temperature and high vacuum, are required in this method. On the contrary, it has low requirement on the apparatus, the process can readily be controlled and a product with high purity can be produced. | 2016-02-25 |
20160052857 | CARBONYLATION PROCESS - A process for the production of methyl acetate by carbonylating dimethyl ether with carbon monoxide in the presence of hydrogen and a zeolite catalyst wherein the process is carried out with a molar ratio of hydrogen to carbon monoxide of at least 1 and the catalyst has been calcined at a temperature of from about 375° C. to about 475° C. | 2016-02-25 |
20160052858 | ALKYL ALPHA-HYDROXYMETHYL ACRYLATES AS REACTIVE SURFACTANTS IN EMULSION POLYMERIZATION - Polymers including α-hydroxymethylacrylate units and methods of preparing polymers from α-hydroxymethylacrylates are provided. Advantageously, α-hydroxymethylacrylates may be used in an emulsion polymerization and function as a polymerizable surfactant. The ability of the α-hydroxymethylacrylates to be used as a polymerizable surfactant allows for emulsion polymerization systems to be prepared without other surfactants. | 2016-02-25 |
20160052859 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN - A compound having a group represented by formula (Ia): | 2016-02-25 |
20160052860 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN - A compound represented by the formula (I). | 2016-02-25 |
20160052861 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN - A compound having a group represented by the formula (Ia): | 2016-02-25 |
20160052862 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF - The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer. | 2016-02-25 |
20160052863 | PROCESS FOR PRODUCING AN AMINOPROPYNE OR ENAMINONE - There is provided a process for producing an aminopropyne or an enaminone comprising the step of reacting a metal acetylide, an amine and a carbonyl-containing compound in the presence of a transition metal catalyst. There is also provided a process for producing an aminopropyne comprising the step of reacting a metal acetylide, an amine and a halide-containing compound in the presence of a transition metal catalyst at a reaction temperature of 50° C. to 150° C. There are also provided processes to further synthesize the aminopropyne produced to obtain a butyneamine, another aminopropyne or a triazol. | 2016-02-25 |
20160052864 | AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN - The present invention relates to unsaturated amine salts of HMG-CoA reductase inhibitors, to a method of producing said amine salts and to the use of said amine salts in the production of pharmaceutically acceptable salts of HMG-CoA reductase inhibitors. | 2016-02-25 |
20160052865 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS - The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection. | 2016-02-25 |
20160052866 | Novel Intermediate Used for Preparing Tapentadol or Analogues Thereof - The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production. | 2016-02-25 |
20160052867 | POLYETHERAMINES BASED ON 1,3-DIALCOHOLS - This invention relates to polyetheramines based on 1,3-dialcohols, in particular to an etheramine mixture comprising at least 90% by weight, based on the total weight of the etheramine mixture, of anamine of Formula (I) and/or (II), wherein R | 2016-02-25 |
20160052868 | Biological buffers with wide buffering ranges - Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability. | 2016-02-25 |
20160052869 | PREPARATION OF LIPOAMINO ACIDS AND LIPOPEPTIDES USING SALTS AS CO-REACTANTS - Methods for synthesizing a lipoamino acid and a lipopeptide are provided. The method can include reacting a fatty acid with an amino acid or a peptide and a co-reactant salt to form a lipoamino acid or a lipopeptide, respectively. The co-reactant salt is generally a magnesium sulfate, magnesium carbonate, potassium carbonate, iron (II) sulfide (troilite), or a mixture thereof. | 2016-02-25 |
20160052870 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS - Disclosed are novel benzamide compounds and the uses thereof for treating diseases and disorders in a patient in need thereof by increasing cellular levels of A3G and/or other members of the A3 family of proteins in the patient. The disclosed compounds include | 2016-02-25 |
20160052871 | NOVEL CURING AGENTS AND DEGRADEABLE POLYMERS AND COMPOSITES BASED THEREON - The present invention provides, among others, compounds of Formula (I) or a salt thereof, methods for making these compounds, degradable polymers and reinforced composites made therefrom, and methods for degrading and/or recycling the degradable polymers and reinforced composites. | 2016-02-25 |
20160052872 | PERFUME COMPOSITIONS CONTAINING ISOMERIC ALKADIENENITRILES - A perfume composition comprising an effective amount of at least one alkadienenitrile selected from 4,8-undecadienenitrile and isomers thereof, 4,9-dodecadienenitrile and isomers thereof, and 4,10-tridecadienenitrile and isomers thereof. The isomers of 4,8-undecadienenitrile comprise Z,Z-4,8-undecadienenitrile, E,E-4,8-undecadienenitrile, and mixed Z/E isomers of 4,8-undecadienenitrile; the isomers of 4,9-dodecadienenitrile comprise Z,Z-4,9-dodecadienenitrile, E,E-4,9-dodecadienenitrile, and mixed Z/E isomers of 4,9-dodecadienenitrile; and the isomers of 4,10-tridecadienenitrile comprise Z,Z-4,10-tridecadienenitrile, E,E-4,10-tridecadienenitrile, and mixed Z/E isomers of 4,10-tridecadienenitrile. A composition comprising an effective amount of at least one alkadienenitrile selected from 4,8-undecadienenitrile and isomers thereof, 4,9-dodecadienenitrile and isomers thereof, and 4,10-tridecadienenitrile and isomers thereof. Processes for the preparation of the isomeric alkadienenitriles are provided. The isomeric alkadienenitriles have a range of fresh, citric, ozonic and floral notes of exceptional strength. | 2016-02-25 |
20160052873 | Novel Intermediate Used for Preparing Tapentadol or Analogues Thereof - The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production. | 2016-02-25 |
20160052874 | METHOD FOR PRODUCING ISOCYANATE - A method for producing an isocyanate, comprising: a carbamation step of generating an N-substituted carbamate from an organic primary amine, urea and an organic hydroxy compound according to a carbamation reaction, and then recovering a first gaseous phase component containing the urea and/or a compound having a carbonyl group derived from the urea, the organic hydroxy compound, and ammonia; a condensation step of condensing the first gaseous phase component with a condenser; an isocyanate production step of producing an isocyanate by subjecting the N-substituted carbamate to pyrolysis; an ammonia absorption step of allowing a second gaseous phase component containing ammonia recovered as a gaseous phase component from the condenser as a main component, to be absorbed by absorption water, and generating gas-absorbed water; and an ammonia stripping step of heating the gas-absorbed water to separate ammonia from the gas-absorbed water. | 2016-02-25 |
20160052875 | METHOD FOR PRODUCING XYLYLENE DIISOCYANATE AND SYSTEM FOR PRODUCING XYLYLENE DIISOCYANATE - A method for producing xylylene diisocyanate includes a thermal decomposition step of thermally decomposing xylylene dicarbamate; a first separation step of separating, from the thermal decomposition product obtained in the thermal decomposition step, an isocyanate-containing component containing xylylene diisocyanate as a main component and an alcohol-containing component containing alcohol as a main component and containing xylylene diisocyanate as a subcomponent; a second separation step of separating xylylene dicarbamate and alcohol from the alcohol-containing component obtained in the first separation step; and a returning step of returning xylylene dicarbamate obtained in the second separation step to the thermal decomposition step. | 2016-02-25 |
20160052876 | CRYOPYRIN INHIBITORS FOR PREVENTING AND TREATING INFLAMMATION - Inhibitors that are anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as heart failure and autoimmune diseases. | 2016-02-25 |
20160052877 | SALT, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN - A salt represented by the formula (I); | 2016-02-25 |
20160052878 | ORGANOCATALYSTS OF OXIDATIVE PROTEIN FOLDING - Catalysts of protein-disulfide isomerization of formula: | 2016-02-25 |
20160052879 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE - Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis. | 2016-02-25 |
20160052880 | Novel CC-1065 Analogs and Their Conjugates - This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor. | 2016-02-25 |
20160052881 | NOVEL CHALCONE DERIVATIVES HAVING AN ANTI-ALLERGIC ACTIVITY - The present invention relates to the compounds of formula (I): | 2016-02-25 |
20160052883 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE - The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension. | 2016-02-25 |
20160052884 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders - The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders. | 2016-02-25 |
20160052885 | METHOD FOR REFINING QUINOLINIC ACID - Provided is a method for refining quinolinic acid, including the steps of: preparing a fermentation solution including at least one of quinolinic acid and a salt thereof; removing microbial cells from the fermentation solution; preparing an acidic composition containing at least one of quinolinic acid and a salt thereof at a saturation concentration or more by adding an acid to the fermentation solution; and recovering a crystal of least one of quinolinic acid and a salt thereof from the acidic composition. | 2016-02-25 |
20160052886 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE - A derivative of nicotinic acid N-oxide is described having formula (I): that acts as inhibitor of enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO), and is thus able to reduce QUIN biosynthesis in vivo under excitotoxic or pathological conditions, said compound being at the same time also chemically stable towards auto-oxidation. | 2016-02-25 |
20160052887 | PHARMACEUTICALLY ACCEPTABLE AMINE SALTS OF PITAVASTATIN - The present invention relates to pharmaceutically acceptable amine salts of pitavastatin and a method for producing pharmaceutically acceptable amine salts of pitavastatin. Also provided are pharmaceutical compositions of these amine salts or solvates thereof, and methods of their use as HMG-CoA reductase inhibitors. | 2016-02-25 |
20160052888 | SUBSTITUTED BICYCLIC COMPOUNDS - Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): | 2016-02-25 |
20160052889 | PHENOXYETHYL DIHYDRO-1H-ISOQUINOLINE COMPOUNDS - The present invention provides a compound of the Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof. | 2016-02-25 |
20160052890 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS - The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of | 2016-02-25 |
20160052891 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN - The present invention relates to a new synthetic intermediate, namely the compound of formula I-2 I or a salt thereof. Said compound of formula I-2 or its salt can be used to prepare the compound of formula I-3 I which is an important synthetic intermediate used in the preparation of macitentan. | 2016-02-25 |
20160052892 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) - The present invention provides novel compounds having a P2X | 2016-02-25 |
20160052893 | PYRIDINE- OR PYRAZINE-CONTAINING COMPOUNDS - Described herein are selective bis-alkynyl pyrazines, bis-alkynyl pyridines, bispyridine substituted ellagic acid derivatives, and pyridine-substituted coumarin derivatives and methods of making thereof. | 2016-02-25 |
20160052894 | BIMODAL LIGANDS WITH MACROCYCLIC AND ACYCLIC BINDING MOIETIES, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING - Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacycicododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders. | 2016-02-25 |
20160052895 | SMALL MOLECULE MEDIATED TRANSCRIPTIONAL INDUCTION OF E-CADHERIN - In one aspect, the invention relates to N-acetamidoalkyl-5-arylisoxazole-3-carboxamide analogs, derivatives thereof, and related compounds, which are useful as mediators of transcriptional induction of E-cadherin; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with E-cadherin activity using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2016-02-25 |
20160052896 | ISOXAZOLE ANALOGS AS MEDIATORS OF TRANSCRIPTIONAL INDUCTION OF E-CADHERIN - In one aspect, the invention relates to N-((arylamino)alkyl)-5-arylisoxazole-3-carboxamide analogs, derivatives thereof, and related compounds, which are useful as mediators of transcriptional induction of E-cadherin; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with E-cadherin activity using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2016-02-25 |
20160052897 | HETEROCYCLIC COMPOUND - The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification. | 2016-02-25 |
20160052898 | NOVEL COMPOUNDS - The present invention relates to substituted N-biphenyl-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disorder, as a sole agent or in combination with other active ingredients. | 2016-02-25 |
20160052899 | METHOD FOR PRODUCING ETHYLENE OXIDE - [Problem] To provide a method by which an amount of production of ethylene glycol as a by-product is reduced and a yield of ethylene oxide can be improved in a process for producing ethylene oxide. | 2016-02-25 |
20160052900 | METHOD FOR PRODUCING ETHYLENE OXIDE - [Problem] To provide a novel technology by which energy efficiency can be further improved in a process for producing ethylene oxide. | 2016-02-25 |
20160052901 | Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum - Disclosed are methods for preparing a mixture of eight diasteromers of vittatalactone | 2016-02-25 |
20160052902 | CATALYTIC SYNTHESIS OF REDUCED FURAN DERIVATIVES - The present invention relates to catalytic synthesis of furan derivatives from alkoxymethylfurfural ethers or acyloxymethylfurfural esters. More particularly, the invention pertains to furan derivatives obtained by use of a multifunctional catalyst system to carry out both hydrogenation of furan starting material and hydrolysis of the reduced furan derivative in a single reaction. The process allows recovering and recycling of alcohol or acid from the reaction product. | 2016-02-25 |
20160052903 | 5-(HYDROXYMETHYL) FURAN-2-CARBALDEHYDE (HMF) SULFONATES AND PROCESS FOR SYNTHESIS THEREOF - 5-(hydroxymethyl)furan-2-carbaldehyde (HMF)-sulfonates and a method of preparing the same are described. The method involves reacting a mixture of 5-(hydroxymethyl)furfural (HMF), with at least one of a) a trifluoromethanesulfonate anhydride (triflate), b) a p-toluene-sulfonyl halide (tosylate), and c) methane-sulfonyl halide (mesylate), and a reagent of either 1) a nucleophilic base or 2) a combination of a non-nucleophilic base and a nucleophile. The HMF-sulfonates (e.g., triflate, tosylate, mesylate, etc. analogs of HMF) can serve as precursor materials from which various derivative compounds can be synthesized. | 2016-02-25 |
20160052904 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE - Inhibitors of EYA tyrosine phosphatase having the structure of Formula I are provided herein. The compounds are useful for the treatment of certain proliferative diseases and cancer. | 2016-02-25 |
20160052905 | USAGE OF MYCOPHENOLATE MOFETIL OR SALT THEREOF IN PREPARING DRUG FOR RESISTING AGAINST INFLUENZA VIRUS - The present invention relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against influenza virus. The present invention also relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against drug-resistant influenza virus strains. The present invention is further related to a method for treating influenza in a subject, comprising administering to said subject an effective amount of mycophenolate mofetil or a pharmaceutically acceptable salt thereof. | 2016-02-25 |
20160052906 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES - A method for manufacturing a compound represented by the following formula (I): | 2016-02-25 |
20160052907 | PROCESS FOR THE PREPARATION OF THIETANE DERIVATIVES - The present invention relates to processes for the preparation of thietane derivatives of the formula IA | 2016-02-25 |
20160052908 | PROCESS FOR THE PREPARATION OF 3-(3-CHLORO-1H-PYRAZOL-1-YL)PYRIDINE - 3-(3-chloro-1H-pyrazol-1-yl)pyridine is prepared by cyclizing 3-hydrazinopyridine-.dihydrochloride with a dialkyl maleate to provide an alkyl 5-oxo-2-(pyridin-3-yl)pyrazolidine-3-carboxylate, by chlorinating to provide an alkyl 3-chloro-1-(pyridin-3-yl)-4,5-dihydro-1H-pyrazole-5-carboxylate, by oxidizing to provide an alkyl 3-chloro-1-(pyridin-3-yl)-1H-pyrazole-5-carboxylate, by converting the ester to the carboxylic acid by hydrolysis to provide 3-chloro-1-(pyridin-3-yl)-1H-pyrazole-5-carboxylic acid hydrochloride, and by removing the carboxylic acid by a decarboxylation reaction. | 2016-02-25 |
20160052909 | GDF-8 Inhibitors - Described are GCF-8 inhibitors of the formula (I), | 2016-02-25 |
20160052910 | COMPOSITIONS AND METHODS FOR CANCER DETECTION AND TREATMENT - Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed. | 2016-02-25 |
20160052911 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS - The invention relates to aryl substituted compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein Het, G, A, R, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain. | 2016-02-25 |
20160052912 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES - Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals. | 2016-02-25 |
20160052913 | SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS - The invention provides modulators of the nociceptin receptor (NOP), including both agonists and antagonists. A compound of the invention can be a selective modulator of NOP with respect to the μ- and κ-opioid receptors (MOP and KOP), thus providing a therapeutic method for the treatment of conditions wherein selective NOP modulation is medically indicated and MOP or KOP modulation may be less desirable. A compound of the invention can be a NOP full agonist, partial agonist, inverse agonist, positive or negative allosteric modulator, or a functionally biased agonist. A compound of the invention can be used for the treatment of an anxiety state, post-traumatic stress disorder, addictive disorders (including overuse of alcohol, tobacco, and drugs of abuse such as cocaine, amphetamines, and opitates), misregulated food intake and/or energy expenditure, cough, sleep disorders, grain, pain, depression, or neurodegenerative disorders such as Parkinsons disease or Alzheimers disease. | 2016-02-25 |
20160052914 | COMPOUNDS AND METHODS FOR MYOTONIC DYSTROPHY THERAPY - The invention provides rationally designed multi-targeting therapeutic agents for myotonic dystrophy type 1 (DM1), an incurable neuromuscular disease that originates in an abnormal expansion of CTG repeats (CTG | 2016-02-25 |
20160052915 | ROHITUKINE ANALOGS AS CYCLIN-DEPENDENT KINASE INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF - The present invention relates to the rohitukine (5,7-dihydroxy-8-(3-hydroxy-1-methyl-piperidin-4-yl)-4H-chromen-4-ones) analogs of formula A and pharmaceutically acceptable salts thereof. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various proliferative disorders such as melanoma, leukemia, breast cancer and prostate cancer etc. [insert Formula A here] wherein, n=0 or 1, when n=1, the dotted line indicates the double bond. | 2016-02-25 |
20160052916 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-- METHYLPYRIDIN-2-YL) BENZOIC ACID - The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. | 2016-02-25 |
20160052917 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE - Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 2016-02-25 |
20160052918 | SMALL COMPOUNDS TARGETING TACC3 - The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents. | 2016-02-25 |
20160052919 | PROCESS FOR THE PREPARATION OF RIVAROXABAN - Disclosed is a process for the preparation of rivaroxaban and purifying rivaroxaban. | 2016-02-25 |
20160052920 | BACE1 INHIBITORS - The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. | 2016-02-25 |
20160052921 | NOVEL 4-METHYL-DIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION - The invention provides novel compounds having the general formula: | 2016-02-25 |
20160052922 | 1-PHENOXY-3-(ALKYLAMINO)-PROPAN-2-OL DERIVATIVES AS CARM1 INHIBITORS AND USES THEREOF - Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R | 2016-02-25 |
20160052923 | PIPERAZINE AND HOMOPIPERAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS - Compounds of Formula I, including pharmaceutically acceptable salts thereof, are useful as HIV attachment inhibitors. | 2016-02-25 |
20160052924 | 2-KETO AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS - Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors. | 2016-02-25 |
20160052925 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN - A method of treatment, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals, particularly in human subjects, comprising administering angiotensin II receptor 2 (AT | 2016-02-25 |
20160052926 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF - The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, | 2016-02-25 |
20160052927 | USE OF ORGANIC OXYIMIDES AS FLAME RETARDANT FOR PLASTIC MATERIALS AND ALSO FLAME-RETARDANT PLASTIC MATERIAL COMPOSITION AND MOULDED PARTS PRODUCED THEREFROM - The present invention relates to the use of organic oxy imides as flame retardants for plastics. According to the present invention, a flame-retardant plastics composition is likewise specified, including an oxy imide as flame retardant. Additionally specified are mouldings produced from an inventive flame-retardant polymer composition. | 2016-02-25 |
20160052928 | INTERMEDIATE OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR - Disclosed are intermediates of Ticagrelor and a preparation method therefor, and a preparation method for Ticagrelor. Specifically, disclosed is an intermediate, namely, a compound of Formula (VI), for preparing Ticagrelor. Further disclosed is a method for preparing the intermediate and a method for preparing Ticagrelor by using the intermediate. Ticagrelor is prepared by using the intermediate, so that the synthesis process is simple, and a defect that long reaction times under high temperature that are required in the existing methods are avoided. The method is suitable for mass production in industry, energy consumption is reduced, pollution of the environment is reduced, and discharge of waste is reduced. | 2016-02-25 |
20160052929 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES - The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) | 2016-02-25 |
20160052930 | AMINOPYRIMIDINYL COMPOUNDS - A compound having the structure: | 2016-02-25 |
20160052931 | DEUTERATED MORPHINE DERIVATIVES - The invention relates to new morphine derivatives deuterated at the 7,8-position of the morphine ring, furthermore to a process for the preparation thereof, and to pharmaceutical compositions comprising them. The new deuterated morphine derivatives show high and selective μ-opioid receptor binding activity leading to the benefit of higher analgesic activity at lower dosages inducing thereby reduced adverse effects compared to the hydrogenated derivatives. The compounds of the invention are useful for example in the treatment of pain or can be used as antitussive agents with a reduced risk of the possibility of drug abuse. | 2016-02-25 |
20160052933 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 2016-02-25 |
20160052934 | RIGID DINITROXIDE BIRADICAL COMPOUNDS USED AS IMPROVED POLARIZING AGENTS FOR DYNAMIC NUCLEAR POLARIZATION TECHNIQUES - The invention concerns a dinitroxide biradical compound, in which the two nitroxide units are held by a rigid linkage, of general formula (I) in which—A is a carbon, an ammonium or a phosphonium, each of A | 2016-02-25 |
20160052935 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY - Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene. | 2016-02-25 |
20160052936 | SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS - Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists. | 2016-02-25 |
20160052937 | Tetrahydroimidazo[1,5-d][1,4]oxazepine compound - A compound represented by formula (I): | 2016-02-25 |
20160052938 | SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS - The present invention encompasses compounds of formula (I) | 2016-02-25 |
20160052939 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS - The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention. | 2016-02-25 |
20160052940 | BIHETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R | 2016-02-25 |
20160052941 | ORGANIC ANION LITHIUM IONIC COCRYSTAL COMPOUNDS AND COMPOSITIONS - A cocrystal having the formula LiX.aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions. | 2016-02-25 |
20160052942 | TRIFLUOROBORATE MASS SPECTROMETRIC TAGS - The invention provides compositions and methods for mass spectrometric (MS), organic synthesis, and applications of organo-trifluoroborate, for example, as mass tags for use in negative ion mode. When subject to MS fragmentation, organo-trifluoroborates preferentially undergo neutral losses of hydrogen fluoride (HF) or boron trifluoride (BF | 2016-02-25 |
20160052943 | METHOD FOR PREPARING OXYBORANE COMPOUNDS - A method for preparing oxyborane compounds of formula (I): using carbon dioxide, and the use of the oxyborane compounds obtained in this way for preparing methane derivatives, in particular oxygenated, halogenated or amino derivatives of methane. The methane derivatives obtained in this way can then be used in the production of vitamins, pharmaceutical products, glues, acrylic fibres and synthetic leathers, pesticides, and fertilisers, for example. Also provided is a method for producing vitamins, pharmaceutical products, glues, acrylic fibres, synthetic leathers, pesticides, and fertilisers, for example, including a step of preparing methane derivatives, in particular oxygenated, halogenated or amino derivatives of methane, from oxyborane compounds obtained by the method according to the invention. Further provided is a method of preparing labelled oxyborane compounds and the use of same. | 2016-02-25 |
20160052944 | Manufacturing Method For High-Purity Glycerol Derivative-Modified Silicone - The present invention relates to a manufacturing method for a liquid high-purity glycerin derivative-modified silicone, the method comprising:
| 2016-02-25 |
20160052945 | PROCESS FOR THE SILYLATION OF 2-AMINO-1,3,5-TRIAZINES - The present invention relates to a method for silylating 2-amino-1,3,5-triazines of the general formula (I) | 2016-02-25 |
20160052946 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF - The present invention discloses a composition comprising a compound of formula I and a deuterated solvent. The deuterated solvent is miscible with water in any proportion at a temperature of 20 to 25° C. and comprises less than 5% residual | 2016-02-25 |
20160052947 | BIS(6-METHYL-3-SULPHOPHENYL)PHENYLPHOSPHINE, AMMONIUM SALT THEREOF, AND METHOD FOR PRODUCING SAME - Provided are a water-soluble triarylphosphine for a palladium catalyst, which has high selectivity in a telomerization reaction and can be recovered with efficiency, an ammonium salt thereof, and a method for efficiently producing the same. Specifically, provided are bis(6-methyl-3-sulphophenyl)phenylphosphine; a bis(6-methyl-3-sulphonatophenyl)phenylphosphine diammonium salt obtained by reacting the phosphine with a tertiary amine having a total of 3 to 27 carbon atoms in groups bonded to one nitrogen atom; and a method for producing the same. | 2016-02-25 |
20160052948 | BIS(6-METHYL-3-SULPHOPHENYL)(2-METHYLPHENYL)PHOSPHINE, AMMONIUM SALT THEREOF, AND METHOD FOR PRODUCING SAME - Provided are a water-soluble triarylphosphine for a palladium catalyst, which has high selectivity in a telomerization reaction and is easily recovered with efficiency, an ammonium salt thereof, and a method for efficiently producing the same. Specifically, provided are bis(6-methyl-3-sulphophenyl)(2-methylphenyl)phosphine; a bis(6-methyl-3-sulphonatophenyl)(2-methylphenyl)phosphine diammonium salt obtained by reacting the phosphine with a tertiary amine having a total of 3 to 27 carbon atoms in groups bonded to one nitrogen atom; and a method for producing the same. | 2016-02-25 |